Shares of Praxis Precision Medicines (PRAX) gained 4.2% on Sept. 4 after the company announced positive top-line data from its mid-stage EMBOLD proof of concept study evaluating relutrigine (PRAX-562) to treat SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. Praxis' EMBOLD Study Reduces Seizures in Epilepsy Patients Data from the phase II EMBOLD study of relutrigine showed that patients treated with relutrigine experienced a placebo-adjusted reduction of 46% in countable monthly mo ...